Name of Journal: *World Journal of Experimental Medicine*

Manuscript NO: 61885

Manuscript Type: ORIGINAL ARTICLE

Retrospective Study

Phase I study on the safety and preliminary efficacy of allogeneic mesenchymal stem cells in hypoxic-ischemic encephalopathy

Serdar Kabataş, Erdinç Civelek, Necati Kaplan, Eyüp Can Savrunlu, Gülseli Berivan Sezen, Mourat Chasan, Halil Can, Ali Genç, Yener Akyuva, Osman Boyalı, Furkan Diren, Erdal Karaoz

59,200 Results Any time

Phase I/II Study of Safety and Preliminary Efficacy of ...

https://pubmed.ncbi.nlm.nih.gov/31495331

The current **study** examined **safety and preliminary efficacy** estimates of intravenous **allogeneic mesenchymal stem cells** in this population. Methods- Entry criteria included **ischemic** stroke >6 months prior and substantial impairment (National Institutes of Health Stroke Scale score ≥6) and disability.

Cited by: 15 **Author:** Michael L. Levy, John R. Crawford, Nabil ...
Publish Year: 2019

Phase I/II Study of Safety and Preliminary Efficacy of ...

https://www.ahajournals.org/doi/full/10.1161/STROKEAHA.119.026318

This was a phase I/II multi-center, open-label **study** that aimed to evaluate the **safety and preliminary efficacy of** a single intravenous infusion of marrow-derived allogeneic ischemia-tolerant MSC. Entry criteria appear in Table 1 and in sum describe enrollment of adults with radiologically verified **chronic stable ischemic stroke** and substantial impairment and functional deficits.

Cited by: 15 **Author:** Michael L. Levy, John R. Crawford, Nabil ...
Publish Year: 2019

[PDF] Phase I/II Study of Safety and Preliminary Efficacy of ...

https://www.ahajournals.org/doi/pdf/10.1161/STROKEAHA.119.026318

laboratory testing. **Preliminary** estimates of treatment **efficacy** were also examined. Methods **Study** Design This was a **phase** I/II multi-center, open-label **study** that aimed to evaluate the **safety and preliminary efficacy** of a single intra-venous infusion of marrow-derived **allogeneic** ...

Cited by: 15 **Author:** Michael L. Levy, John R. Crawford, Nabil ...
Publish Year: 2019

Phase I/II Study of Safety and Preliminary Efficacy of ...

https://www.stemcellsgroup.com/intravenous...

Phase I/II **Study** of **Safety and Preliminary Efficacy** of Intravenous **Allogeneic Mesenchymal Stem Cells** in Chronic Stroke Michael L. Levy, MD, PhD; John R. Crawford, MD; Nabil Dib, MD; Lev Verkh, PhD; Nikolai Tankovich, MD, PhD; Steven C. Cramer, MD Background and Purpose—Stroke is a leading cause of long-term disability. Limited treatment options exist

国内版 国际版

Phase I study on the safety and preliminary efficacy of allogeneic m

ALL IMAGES VIDEOS

57,800 Results Any time Open links in new tab

Phase I/II Study of Safety and Preliminary Efficacy of ...

https://pubmed.ncbi.nlm.nih.gov/31495331

The current **study** examined **safety and preliminary efficacy** estimates of intravenous **allogeneic mesenchymal stem cells** in this population. Methods- Entry criteria included ischemic stroke >6 months prior and substantial impairment (National Institutes of Health Stroke Scale score ≥6) and disability.

Cited by: 22 **Author:** Michael L. Levy, John R. Crawford, Nabil …
Publish Year: 2019

Phase I/II Study of Safety and Preliminary Efficacy of ...

https://www.ahajournals.org/doi/full/10.1161/STROKEAHA.119.026318

This was a **phase** I/II multi-center, open-label **study** that aimed to evaluate the **safety and preliminary efficacy** of a single intravenous infusion of marrow-derived **allogeneic** ischemia-tolerant MSC. Entry criteria appear in Table 1 and in sum describe enrollment of adults with radiologically verified chronic stable ischemic stroke and substantial ...

Cited by: 22 **Author:** Michael L. Levy, John R. Crawford, Nabil …
Publish Year: 2019

[PDF] Phase I/II Study of Safety and Preliminary Efficacy of

57,800 Results Any time

Phase I/II Study of Safety and Preliminary Efficacy of ...

https://pubmed.ncbi.nlm.nih.gov/31495331

The current **study** examined **safety and preliminary efficacy** estimates of intravenous **allogeneic mesenchymal stem cells** in this population. Methods- Entry criteria included ischemic stroke >6 months prior and substantial impairment (National Institutes of Health Stroke Scale score ≥6) and disability.

Cited by: 22 **Author:** Michael L. Levy, John R. Crawford, Nabil Di...
Publish Year: 2019

Phase I/II Study of Safety and Preliminary Efficacy of ...

https://www.ahajournals.org/doi/full/10.1161/STROKEAHA.119.026318

This was a **phase** I/II multi-center, open-label **study** that aimed to evaluate the **safety and preliminary efficacy** of a single intravenous infusion of marrow-derived **allogeneic** ischemia-tolerant MSC. Entry criteria appear in Table 1 and in sum describe enrollment of adults with radiologically verified chronic stable ischemic stroke and substantial ...

Cited by: 22 **Author:** Michael L. Levy, John R. Crawford, Nabil Di...
Publish Year: 2019

A Study of Allogeneic Mesenchymal Bone Marrow Cells in ...

https://clinicaltrials.gov/ct2/show/NCT01297413

Levy ML, Crawford JR, Dib N, Verkh L, Tankovich N, Cramer SC. **Phase** I/II **Study** of **Safety and Preliminary Efficacy** of Intravenous **Allogeneic Mesenchymal Stem Cells** in Chronic Stroke. Stroke. 2019 Oct;50(10):2835-2841. doi: 10.1161/STROKEAHA.119.026318. Epub 2019 Sep 9.

[PDF] Phase I/II Study of Safety and Preliminary Efficacy of ...

https://www.ahajournals.org/doi/pdf/10.1161/STROKEAHA.119.026318

laboratory testing. **Preliminary** estimates of treatment **efficacy** were also examined. Methods **Study** Design This was a **phase** I/II multi-center, open-label **study** that aimed to evaluate the **safety and preliminary efficacy** of a single intra-venous infusion of marrow-derived **allogeneic** ...

Cited by: 22 **Author:** Michael L. Levy, John R. Crawford, Nabil Di...
Publish Year: 2019

A Study of Allogeneic Mesenchymal Bone Marrow Cells in ...

https://clinicaltrials.gov/ct2/show/NCT01770613